Joseph J Palamar1, Alberto Salomone2, Enrico Gerace2, Daniele Di Corcia2, Marco Vincenti3, Charles M Cleland4. 1. New York University Langone Medical Center, Department of Population Health, New York, NY, USA; Center for Drug Use and HIV Research, New York University Rory Meyers College of Nursing, New York, NY, USA. Electronic address: joseph.palamar@nyumc.org. 2. Centro Regionale Antidoping e di Tossicologia "A. Bertinaria", Orbassano, Turin, Italy. 3. Centro Regionale Antidoping e di Tossicologia "A. Bertinaria", Orbassano, Turin, Italy; Dipartimento di Chimica, Università di Torino, Turin, Italy. 4. Center for Drug Use and HIV Research, New York University Rory Meyers College of Nursing, New York, NY, USA; New York University Rory Meyers College of Nursing, New York, NY, USA.
Abstract
BACKGROUND: Data on both known and unknown drug use in the electronic dance music (EDM) scene is important to inform prevention and harm reduction. While surveys are the most common method of querying drug use, additional biological data can help validate use and detect unknown/unintentional use of drugs such as new psychoactive substances (NPS). We sought to determine the extent of both known and unknown use of various substances in this high-risk scene. METHODS: We hair-tested 90 self-reported past-year ecstasy/MDMA/Molly users attending EDM parties in New York City during the summer of 2016 using UHPLC-MS/MS. Results were compared to self-reported past-year use. RESULTS: Three quarters (74.4%) tested positive for MDMA, a third (33.3%) tested positive for an NPS, and 27.8% tested positive specifically for one or more synthetic cathinones (e.g., butylone, ethylone, pentylone, methylone, alpha-PVP). Half (51.1%) of participants tested positive for a drug not self-reported, with most testing positive for synthetic cathinones (72.0%), methamphetamine (69.0%), other NPS stimulants (e.g., 4-FA, 5/6-APB; 66.7%), or new dissociatives (e.g., methoxetamine, diphenidine; 60.0%). Attending parties every other week or more often, reporting higher-frequency ecstasy pill use, having tested one's ecstasy, and having found out one's ecstasy was adulterated, were risk factors for testing positive for synthetic cathinones and NPS in general. CONCLUSION: Hair testing appears to be a valuable addition to drug epidemiology studies. Many EDM party attendees-even those who test their ecstasy-are unknowingly using NPS and/or other drugs. Prevention information and harm reduction may help reduce unknown/unintentional use.
BACKGROUND: Data on both known and unknown drug use in the electronic dance music (EDM) scene is important to inform prevention and harm reduction. While surveys are the most common method of querying drug use, additional biological data can help validate use and detect unknown/unintentional use of drugs such as new psychoactive substances (NPS). We sought to determine the extent of both known and unknown use of various substances in this high-risk scene. METHODS: We hair-tested 90 self-reported past-year ecstasy/MDMA/Molly users attending EDM parties in New York City during the summer of 2016 using UHPLC-MS/MS. Results were compared to self-reported past-year use. RESULTS: Three quarters (74.4%) tested positive for MDMA, a third (33.3%) tested positive for an NPS, and 27.8% tested positive specifically for one or more synthetic cathinones (e.g., butylone, ethylone, pentylone, methylone, alpha-PVP). Half (51.1%) of participants tested positive for a drug not self-reported, with most testing positive for synthetic cathinones (72.0%), methamphetamine (69.0%), other NPS stimulants (e.g., 4-FA, 5/6-APB; 66.7%), or new dissociatives (e.g., methoxetamine, diphenidine; 60.0%). Attending parties every other week or more often, reporting higher-frequency ecstasy pill use, having tested one's ecstasy, and having found out one's ecstasy was adulterated, were risk factors for testing positive for synthetic cathinones and NPS in general. CONCLUSION: Hair testing appears to be a valuable addition to drug epidemiology studies. Many EDM party attendees-even those who test their ecstasy-are unknowingly using NPS and/or other drugs. Prevention information and harm reduction may help reduce unknown/unintentional use.
Authors: Elena Lendoiro; Cristian Jiménez-Morigosa; Angelines Cruz; Mario Páramo; Manuel López-Rivadulla; Ana de Castro Journal: Drug Test Anal Date: 2016-02-24 Impact factor: 3.345
Authors: Sarah M R Wille; Elke Raes; Pirjo Lillsunde; Teemu Gunnar; Marleen Laloup; Nele Samyn; Asbjørg S Christophersen; Manfred R Moeller; Karin P Hammer; Alain G Verstraete Journal: Ther Drug Monit Date: 2009-08 Impact factor: 3.681
Authors: Matt S Friedman; Alex Plocki; Antonios Likourezos; Illya Pushkar; Andrew N Bazos; Christian Fromm; Benjamin W Friedman Journal: Prehosp Disaster Med Date: 2016-12-16 Impact factor: 2.040
Authors: Trond Nordfjærn; Anne Line Bretteville-Jensen; Marit Edland-Gryt; Johanna Gripenberg Journal: Scand J Public Health Date: 2016-09-25 Impact factor: 3.021
Authors: Joseph J Palamar; Alberto Salomone; Rachele Bigiarini; Marco Vincenti; Patricia Acosta; Babak Tofighi Journal: Am J Drug Alcohol Abuse Date: 2019-01-02 Impact factor: 3.829